Stryker to Acquire Amplitude Vascular Systems

Stryker Corp. is purchasing Amplitude Vascular Systems Inc. (AVS), a privately held medical technology firm developing a next-generation intravascular lithotripsy (IVL) platform for treating calcified peripheral arterial disease. Neither company disclosed the deal’s financial terms.

The acquisition adds revascularization technology to Stryker’s Peripheral Vascular (PV) portfolio. Once cleared for use in applicable markets, the product will complement its existing PV offerings and support the company’s goal to expand its market presence in arterial disease treatment.

“This acquisition represents an important step in advancing our vision to build a comprehensive peripheral vascular platform and address significant unmet clinical needs,” Stryker Chair/CEO Kevin Lobo stated. “Combining this innovation with Stryker’s scale and clinical expertise, we believe we can help expand treatment options for physicians and improve care for patients with calcified peripheral arterial disease.”

AVS’ technology uses pulsed CO₂-generated pressure waves uniformly delivered through an IVL balloon catheter, to fracture calcium and optimize luminal gain. The platform aims to enhance catheter deliverability, treatment speed, and therapy efficiency.

IVL is a fast-growing technology in cardiovascular intervention and is used to treat calcified peripheral and coronary lesions. It is expected to experience strong growth as physicians adopt IVL-based calcium modification in complex procedures.

This transaction is subject to customary closing conditions. Stryker and AVS will continue to operate as separate entities and proceed with business as usual until the transaction closes. A timetable for closing the deal was not provided.

Stryker develops, manufactures, and markets products and services in MedSurg, Neurotechnology, and Orthopaedics that help improve patient and healthcare outcomes. Its solutions impact more than 150 million patients annually.

Amplitude Vascular Systems is a medical device company based in Boston focused on treating severely calcified arterial disease. Backed by global investors including BioStar Capital, Cue Growth Partners, and others, AVS was founded in 2017 by Hitinder Gurm, M.D., an interventional cardiologist and chief clinical officer at the University of Michigan; and Robert Chisena, Ph.D., chief technical officer at AVS.